Either an even more efficient suppression of HIV replication is required to achieve protection from the associated Burkitt’s and Hodgkin’s lymphomas or therapeutic vaccination to elicit T cell responses that target the EBV antigens that are expressed in these tumors (EBNA1, LMP1 and LMP2) could be considered [33]. The gene discussed is PDLIM7; the disease is Hodgkins lymphoma.